Patients with systemic lupus erythematosus (SLE) who attain a low disease state have a lower risk of subsequent disease…
Articles by Patricia Inacio, PhD
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has been awarded a three-year $2.4-million grant from the U.S.
Progentec, a company developing new diagnostic technologies for chronic conditions, has been awarded $1.7 million to validate its blood…
Attaining a low disease state — deemed Lupus Low Disease Activity State or LLDAS — has become a major…
The Lupus Research Alliance (LRA) and its affiliate Lupus Therapeutics have expanded a collaboration with Bristol-Myers Squibb to help…
KZR-616, a selective immunoproteasome inhibitor, is safe, well-tolerated, and effectively reduces disease activity in patients with active systemic lupus…
Mallinckrodt Pharmaceuticals has completed enrollment for its Phase 4 clinical trial evaluating the safety and effectiveness of H.P. Acthar Gel (repository corticotropin…
Equillium announced that it is planning to test EQ001, its monoclonal antibody, in a Phase 1b trial as a potential…
The Lupus Research Alliance and its affiliate, Lupus Therapeutics, have partnered with Takeda Pharmaceutical to conduct a Phase 1 clinical trial…
Physical fitness, particularly muscle strength and cardiorespiratory fitness, are associated with better quality of life scores in women with systemic…